Screener
Immix Biopharma, Inc. IMMX Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | 2026 / For the Three Months Ended / March 31, | 2025 / For the Three Months Ended / March 31, |
|---|---|---|
| Other income (expense): | ||
| Interest income | 717,168 | 150,219 |
| Total other income (expense), net | 717,168 | 150,219 |
| Loss before provision for income taxes | (10,086,687) | (4,532,706) |
| Provision for income taxes | - | 9,822 |
| Net loss | (10,086,687) | (4,542,528) |
| Other comprehensive income: | ||
| Unrealized gains on available-for-sale securities | 69,141 | - |
Document
FAQ
- What is Immix Biopharma, Inc.'s pre-tax income?
- Immix Biopharma, Inc. (IMMX) reported pre-tax income of -$10.09M in Q1 2026.
- How has Immix Biopharma, Inc.'s pre-tax income changed year-over-year?
- Immix Biopharma, Inc.'s pre-tax income decreased by 122.5% year-over-year, from -$4.53M to -$10.09M.
- What is the long-term trend for Immix Biopharma, Inc.'s pre-tax income?
- Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s pre-tax income has grown at a 4.8% compound annual growth rate (CAGR), from -$24.38M to -$29.4M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about Immix Biopharma, Inc.'s pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude